Faecalibacterium prausnitzii: A Keystone Gut Microbe

Learn what Faecalibacterium prausnitzii does, how GI-MAP measures it, and why a low result cannot diagnose inflammation or a butyrate deficiency.

Educational overview · Updated 9 October 2026 · Reviewed by Madison Ordway, FDN-P.

Key facts

  • What it is: a common gut bacterium studied for its butyrate production.
  • On the GI-MAP: a DNA abundance result in the commensal bacteria section.
  • A low result: needs context; it does not establish a disease or a need for supplements.
  • What it cannot measure: this bacterial result does not directly measure butyrate production or inflammation.

Faecalibacterium prausnitzii is a bacterium that normally lives in the human gut. Researchers study it because it produces butyrate, a short-chain fatty acid, and because some studies associate lower abundance with inflammatory bowel disease. Those findings explain interest in the organism; they do not make an individual stool result a diagnosis. [1]

Why it is called a keystone microbe

The term describes its potential contribution to the gut ecosystem. In a 2008 study, lower proportions in intestinal tissue from people having Crohn disease surgery were associated with recurrence six months later. Separate cell and mouse experiments investigated anti-inflammatory effects. This was not a study validating GI-MAP stool results or showing that raising this bacterium treats people with Crohn disease. [1]

What GI-MAP measures

Diagnostic Solutions Laboratory uses quantitative PCR (qPCR) to detect and quantify targeted microbial DNA in stool. The F. prausnitzii result describes the amount of its target DNA in that sample. It does not directly measure how much butyrate the bacteria are making, and a targeted panel does not describe every organism in the gut. [2]

See the sample GI-MAP report for the format and the interpretive guide for reading results in context.

What does low Faecalibacterium prausnitzii mean?

A low flag means the measured result falls below that laboratory's reference interval. It does not, by itself, establish reduced anti-inflammatory capacity, a butyrate deficiency, Crohn disease or ulcerative colitis. International expert guidance cautions against inferring microbiome metabolic function from the organisms present. [3]

For example: a low bacterial result and a result for fecal calprotectin answer different questions. The first concerns a bacterial DNA target; the second is a separate stool inflammation marker. One cannot substitute for the other.

Take the report to the clinician managing your symptoms. Bring your symptom history, usual diet and medication or supplement list so the result can be considered alongside other findings. [3]

Frequently asked questions

Is Faecalibacterium prausnitzii good or bad?

It is generally described as a beneficial commensal, meaning a normal resident of the gut. Its research associations do not establish that a higher stool number is always better. [1]

Does a low result mean I need a probiotic or supplement?

No. A low abundance result alone does not identify an effective product, dose or treatment. Discuss a specific health concern with your clinician instead of choosing a supplement solely to change this number. [3]

Is GI-MAP a butyrate test?

The Faecalibacterium prausnitzii result on GI-MAP measures a bacterial DNA target. It is not a direct measurement of butyrate or of the bacteria's activity in your gut. [2]

Explore what the report includes before deciding whether testing fits your needs.

View the sample report → See test costs

References

  1. Sokol H, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. PNAS. 2008;105:16731–16736. Original study.
  2. Diagnostic Solutions Laboratory. GI-MAP Methodology Guide. Laboratory source for the assay method; accessed 9 October 2026.
  3. Porcari S, et al. International consensus statement on microbiome testing in clinical practice. Lancet Gastroenterology & Hepatology. 2025;10:154–167. General interpretation guidance, not a validation study of GI-MAP.

Editorial status

Reviewed by Madison Ordway, FDN-P. Review standards.

Updated against the sources listed above on 9 October 2026. This revision has been reviewed by Madison Ordway, FDN-P. This page explains a laboratory marker and does not provide an individual diagnosis or treatment plan.

See your own gut markers

Order the GI-MAP™ and get 85+ quantified markers from a single at-home sample. Free shipping to your door, lab-analyzed results.

Order Your GI-MAP™ Test →
Order Your GI-MAP™ Test →